

Ausgabe: Prophylaxe Journal 1/2018

Thema: Antiresorptive Medikamente – Die Bedeutung bei parodontologischen Therapien

Autoren: Dr. Julia Blank, Prof. Dr. Georg Gaßmann

Literatur

1. **Grötz KA, Piesold JU, Al-Nawas B.** Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. S3-Leitlinie. AWMF online 2012. http://www.awmf.org/uploads/tx_szleitlinien/007-091I_S3_Bisphosphonat-assoziierte_Kiefernekrose_2012_ungueltig.pdf; letzter Zugriff 17.12.17.
2. **Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG.** The relationship between the chemistry and biological activity of the bisphosphonates. *Bone* 2011; 49(1):20-33.
3. **Russell RG, Watts NB, Ebetino FH, Rogers MJ.** Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. *Osteoporos Int* 2008; 19(6):733-759.
4. **Bock O.** Die Wirkung der antiresorptiven Therapie am Knochen. *Osteologie* 2012; 2:63-69.
5. **Marx RE.** Pamidronate (Aredia) and zoledronate (Zometa) induced a vascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* (2003) 61:1115-1117.
6. **Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B.** American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. *J Oral Maxillofac Surg* 2009; 5:2-12.
7. **Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN.** Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. *J Bone Miner Res* 2008; 23(6):826-836.
8. **Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E.** Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. *Clin Oral Investig*. 2010; 14(3):311-317.
9. **Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL.** Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *J Oral Maxillofac Surg* 2004; 62(5):527-534.

10. **Then C, Hörauf N, Otto S, Pautke C, Tresckow E, Röhnisch T, Baumann P, Schmidmaier R, Bumeder I, Oduncu FS.** Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. *Onkologie* 2012; 35:658-664.
11. **Felsenberg D, Hoffmeister B, Amling M, Mundlos S, Seibel M, Fratzl P.** Onkologie: Kiefernekrosen nach hochdosierter Bisphosphonattherapie. *Deutsches Ärzteblatt* 2006; 103:3078-3080.
12. **Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.** Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *Clin Oncol.* 2010; 28(35):5132-5139.
13. **Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.** Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet.* 2011 Mar 5;377(9768):813-822.
14. **Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, Russo PA, Kreuzsch T.** "Bis-phoshy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. *J Craniomaxillofac Surg.* Mar 2008; 36(2):95-103.
15. **Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, Pautke C.** Bisphosphonate-related osteonecrosis of the jaws - Characteristics, risk factors, clinical features, localization and impact on oncological treatment. *J Craniomaxillofac Surg* 2011; 40(4):303-309.
16. **Grötz KA, Kreuzsch T.** Zahnärztliche Betreuung von Patienten unter/ nach Bisphosphonat Medikation. Gemeinsame wissenschaftliche Stellungnahme der DGZMK, AG Kieferchirurgie und DGMKG. DZZ 2006. http://www.dgzmk.de/uploads/tx_szdgzmkdocuments/Zahnaerztliche_Betreuung_von_Patienten_unternach_Bisphosphonat-Medikation.pdf; letzter Zugriff 17.12.2017.
17. **Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV.** Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. *Oncology* 2009; 76(3):209-211.
18. **Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P.** Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. *Breast Cancer Res Treat* 2010; 122(1):181-188.

19. **Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G.** Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. *Oral Oncol.* 2008; 44(9):857-869.
20. **Hess LM, Jeter JM, Ham-Hutchins M, Alberts DS.** Factors associated with osteonecrosis of the jaw among bisphosphonate users. *Am J Med* 2008; 121(6):475-483.
21. **Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.** Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. *Eur Urol* 2008; 54(5):1066-1072.
22. **Marx RE, Sawatari Y, Fortin M, Broumand V.** Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. *J Oral Maxillofac Surg* 2005; 63(11):1567-1575.
23. **Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniadis K.** Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. *J Clin Oncol* 2009; 27(32):5356-5362.
24. **Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A.** Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. *Ann Oncol* 2009; 20:117-120.
25. **Bonacina R, Mariani U, Villa F, Villa A.** Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. *J Can Dent Assoc* 2011; 77:147.
26. **Sim W, Sanders KM, Borromeo GL, Seymour JF, Ebeling PR.** Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer. *J Clin Endocrinol Metab* 2015; 100:3887-3893.
27. **Shepherd GM.** Hypersensitivity reactions to drugs: evaluation and management. *Mt Sinai J Med* 2003; 70:113–125.
28. **McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM.** Bisphosphonate therapy for osteoporosis: benefits, risks and drug holiday. *Am J Med* 2013; 126:13-20.
29. **Saad F, Lipton A.** Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. *Semin Oncol* 2007; 34:17-23.
30. **Crawford BS, McNulty RM, Kraut EH, Turowski RC.** Extended use of intravenous bisphosphonate therapy for prevention of skeletal complications in patients with cancer. *Cancer Invest* 2009; 27(10):984-988.